1999
DOI: 10.1054/jhsb.1999.0235
|View full text |Cite
|
Sign up to set email alerts
|

Recurrent Osteoblastoma of the Hamate Bone

Abstract: An osteoblastoma in a carpal bone is very rare and presents a problem of reconstruction after wide tumour excision. We report a case of recurrent osteoblastoma of the right hamate bone with involvement of the ulnar carpal bones and soft tissues that was successfully treated by en bloc resection, temporary interposition of bone cement and fixation with K-wires, followed by reconstruction with a free vascularized iliac crest flap, tailored to the exact size of the defect, in a second procedure. Rapid fusion was … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2004
2004
2024
2024

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 9 publications
(1 citation statement)
references
References 14 publications
0
1
0
Order By: Relevance
“…When ABCs of the hamate have complete cortical involvement, total hamate excision is a reasonable option that maintains wrist function and stability at the 3-year mark. 86 Osteoblastomas of the hamate have a tendency to recur after curettage and can be treated with total excision and carpal fusion involving either a vascularized iliac free flap 87 or a fifth carpometacarpal (CMC) arthrodesis. 88 Both techniques provide positive functional outcomes with no osteoblastoma recurrence at the 3- and 4-year follow-up, respectively.…”
Section: Hamatementioning
confidence: 99%
“…When ABCs of the hamate have complete cortical involvement, total hamate excision is a reasonable option that maintains wrist function and stability at the 3-year mark. 86 Osteoblastomas of the hamate have a tendency to recur after curettage and can be treated with total excision and carpal fusion involving either a vascularized iliac free flap 87 or a fifth carpometacarpal (CMC) arthrodesis. 88 Both techniques provide positive functional outcomes with no osteoblastoma recurrence at the 3- and 4-year follow-up, respectively.…”
Section: Hamatementioning
confidence: 99%